Patent · US Active

Systems and methods for treating cancer

US10993946B2 · kind B2 · utility

1Cited by
0References
20Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 10, 2019
Grant dateMay 4, 2021
Priority date
Expiry dateSep 10, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2300/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject; (b) determining if at least a portion of the sample of the cancer cells is LKB1 deficient; and (c) contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising contacting the cancer cells with a therapeutically effective amount of a Wee1 inhibitor and a therapeutically effective amount of a second pharmaceutical composition. Embodiments of the invention also provide a method of prognosing or determining the severity of cancer in a subject comprising (a) determining the presence or absence of LKB1 in the cancer cells of the subject; and (b) prognosing the severity of cancer based on the presence of LKB1 deficiency in the cancer cells …

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.